Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bretten – page 30

1 040 clinical trials in Bretten, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bretten at a glance
1 040
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 040 trials in Bretten

Open in trial search

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study of Nivolumab for Patients with Metastatic Solid Tumors and Leptomeningeal Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Glioblastoma

Recruiting

Study of Meclofenamate Sodium and Temozolomide for Patients with Progressive MGMT-Methylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Meclofenamate Sodium
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Study on the Safety and Effectiveness of Linvoseltamab, Sarilumab, and Dexamethasone in Adults with Relapsed or Refractory AL Amyloidosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Amivantamab, Pembrolizumab, and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Universitaetsklinikum Essen AöR

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sparsentan
  • Sponsor:Travere Therapeutics Inc.

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bretten

What the registry says about research in the country

01 Infectious Disease Prevention

Ongoing clinical trials focusing on meningococcal infection prevention through vaccination studies. Research is evaluating the long-term effectiveness of a quadrivalent conjugate vaccine in providing protection against multiple bacterial strains.

  • Vaccine Immunogenicity
  • Long-term Protection
  • Pediatric Vaccination

Studies involve children and adolescents across multiple European centers, examining immune responses and safety profiles of booster vaccinations administered at 5- and 10-year intervals.

02 Pediatric Immunology

Research centered on understanding the persistence of immunity in young populations. The booster vaccination studies are specifically designed to evaluate immune system responses in previously vaccinated children.

  • Immune Response Duration
  • Booster Effectiveness
  • Safety Assessment

These trials are being conducted across multiple sites in Finland, Germany, Spain, and Hungary, focusing on protective immunity development in pediatric populations.

03 Preventive Medicine

Investigation of preventive strategies against multiple meningococcal serogroups through advanced vaccine technology. The research aims to establish optimal timing for booster doses.

  • Multi-strain Protection
  • Vaccination Schedule Optimization
  • Population Health Impact

The study evaluates the effectiveness of vaccination strategies in providing comprehensive protection against various meningococcal strains.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.